Company
monod.bio
Revolutionizing life sciences tools and clinical diagnostics with Computational Protein Design
Also known as Monod Bio, Inc.
- Status
- Operatingas of 2026-09-19
- Business model
- B2B
- Founded
- 2022
- Customers
- enterprise customers and their representatives
- Legal name
- Monod Bio, Inc.
- monod.bio (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Monod Bio is a pioneer company in the design of de novo protein RUO tools, biosensors, and IVD. Our innovative de novo protein design platform takes advantage of the most recent advances in computational protein engineering to create highly modular reporters, binders, and biosensors that enable rapid, sensitive, and inexpensive analytical assays.
Funding snapshot
- Total raised
- $30.2MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $24.2M2022-06-10
Funding rounds
- Round, 2022
- $24.2M2022-06-10, SEC form D sold, 31 investors
- Round, 2021
- $6M2021-11-29, SEC form D sold, 27 investors
Products
- Other
- CRP Biosensor on NovoLISA Platform
- Other
- LuxSit Pro
Loading relationship preview